Regional Early-Stage Venture Capital · Private Equity, VC & Investor
Breega
European and African early-stage venture capital fund manager.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- BREEGA
- Entity type
- COMPANY
- Founded
- 2013
- Headquarters
- France
- Company size
- 10–49
- Market cluster / sector
- Regional Early-Stage Venture Capital
- Market role
- Private Equity, VC & Investor
- Official website
- breega.com
What Breega does
Breega operates as a venture capital and fund management business. It raises committed capital into investment vehicles, allocates that capital into startups, and aims to generate returns through equity value appreciation and exits. Value is created through sourcing deals, selecting founders, supporting portfolio companies operationally, and maintaining regional coverage that helps it access opportunities across Europe and Africa.
Category differentiation
Breega is a venture capital and fund management firm, not a software vendor, accelerator, or startup studio. It should be distinguished from portfolio companies it funds and from general business consultancies.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Breega is a France-headquartered venture capital firm founded in 2013. It manages early-stage investment funds and deploys capital into startups, with explicit operating presence in Paris and London and stated coverage across Europe and Africa. Available evidence indicates it manages approximately €700 million in assets and has launched region-specific vehicles including Europe Seed III and Breega Africa Seed I. Its business model is that of a regulated fund manager: it raises capital from limited partners, invests that capital into private companies, supports portfolio development, and seeks returns through future exits. Its direct economic customers are fund investors, while its operating counterparties are startup founders and portfolio companies seeking seed-stage capital and strategic support.
Business model & monetisation
The core monetisation model is venture fund economics: recurring management fees on assets under management and performance-based carried interest on profitable exits. Commercially, this is closer to asset management and investment upside participation than software subscription revenue.
- Fund management fees
- Recurring fees on committed or managed capital
- Carried interest
- Performance participation on investment gains after exits
- Co-investment or ancillary investment-related income
- Transaction-specific participation where applicable
Products & capabilities
No products with linked sources are available in this view.
POLARIS7 WORKSPACE
Go deeper on Breega and its market context
Access extended corporate structures, historical M&A and partnership links, technical footprint data, and automated Watchlist briefings grounded in primary sources.
- Corporate & subsidiary hierarchy
- Competitor & partner network
- Automated Watchlist briefings
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Breega's competitive landscape.
European venture capital firm for technology startups and growth companies.
Multi-stage venture capital and fund management firm.
French seed VC backing European founders with global ambition.
European seed venture fund for early-stage software startups.
French early-stage venture capital firm backing founders from seed onward.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Cori Clinical Raises €3.8M to Accelerate Clinical Trials
Funding · Recorded impact score: 1/5
London-based Cori Clinical, a startup providing an AI-powered intelligence layer for clinical trials, has raised €3.8 million in a Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use the funds to expand delivery capacity, grow its team, and deepen regulatory and clinical intelligence in its platform. Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health. Founded in 2025 by Jorn Jansen Schoonhoven (CEO) and Patricio Fernández (CTO), Cori Clinical creates a 'living blueprint' for trials, integrating internal knowledge with external data from registries and regulatory bodies like FDA, MHRA, and EMA. The startup claims its approach could reduce average trial set-up costs by at least 33%. It already works with two of the top five global CROs and has customers like Erasmus MC.
- Cori Clinical raised €3.8 million in a Seed round led by Breega.
- Participants include Enzo, Heartfelt, Together Ventures, and Bynd.
Explore company relationships
Questions about Breega
What is Breega?
Breega is a France-based venture capital firm that manages early-stage investment funds focused on startups across Europe and Africa.
Who uses Breega?
Its direct economic customers are limited partners investing in its funds, while founders and startups engage with Breega for seed capital and support.
How does Breega make money?
Breega primarily earns management fees on funds under management and carried interest from successful portfolio exits.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
1 publicly documented primary sources and citations linked across the market graph.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
Breega
Open extended company details, ownership links, and automated signal monitoring in Polaris7.
